The effect of evolocumab alone and in combination with atorvastatin on atherosclerosis progression and TLRs expression.

Saud, Ali; Ali, Nabeel; Gali, Fadhil; Qassam, Heider; Hadi, Najah Rayish

Saud, Ali; Ali, Nabeel; Gali, Fadhil; Qassam, Heider; Hadi, Najah Rayish.

Afiliación

Saud A; Department of Pharmacology and Therapeutics, College of Medicine, University of Kufa, Najaf, Iraq.
Ali N; Department of Pharmacology, College of Medicine, University of Basra, Basra, Iraq.
Gali F; Department of Pharmacology &Therapeutics, Faculty of Medicine, University of Kufa, Najaf, Iraq.
Qassam H; Department of Pharmacology &Therapeutics, Faculty of Medicine, University of Kufa, Najaf, Iraq.
Hadi NR; Department of Pharmacology &Therapeutics, Faculty of Medicine, University of Kufa, Najaf, Iraq.

J Med Life ; 16(5): 759-765, 2023 May.

Article en En | MEDLINE | ID: mdl-37520489

Asunto(s)

Aterosclerosis; Interleucina-17; Animales; Masculino; Conejos; Atorvastatina/farmacología; Atorvastatina/uso terapéutico; Aterosclerosis/tratamiento farmacológico; LDL-Colesterol; Resultado del Tratamiento

Palabras clave

CSK: Preprotein Convertase Subtilisin/Kexin 9 (alternative abbreviation); ICAM: Intracellular Adhesion Molecule; IL: Interleukin; LDL-C: Low-Density Lipoprotein-Cholesterol; PCSK9: Proprotein Convertase Subtilisin/Kexin 9; TC: Total Cholesterol; TG: Triglycerides; TLRs; TLRs: Toll-like receptors; VCAM: Vascular Adhesion Molecule; atherosclerosis; atorvastatin; evolocumab

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Interleucina-17 / Aterosclerosis Límite: Animals Idioma: En Revista: J Med Life Asunto de la revista: MEDICINA Año: 2023 Tipo del documento: Article País de afiliación: Irak Pais de publicación: Rumanía

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google